Related references
Note: Only part of the references are listed.HER2 and responsiveness of breast cancer to adjuvant chemotherapy
KI Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
L Del Mastro et al.
BRITISH JOURNAL OF CANCER (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer
A Moliterni et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer:: a prospective randomised study
M Colozza et al.
EUROPEAN JOURNAL OF CANCER (2002)
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
MJ Piccart et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23
B Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
S Paik et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
TAH Jarvinen et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
